Bladder, kidney, and other urologic cancers:
Indications for DEPO-PROVERA:
As adjunctive and palliative treatment of inoperable, recurrent, and metastatic renal carcinoma.
Initially 400–1000mg IM every week. If improvement noted and disease stabilized within a few weeks or months, may be possible to maintain at 400mg per month.
Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease.
Risk of bone mineral density (BMD) loss. Evaluate BMD with long-term use or in adolescents. Previous or family history of breast cancer (monitor closely). History of depression; monitor and discontinue if serious depression recurs. Diabetes. Conditions aggravated by fluid retention (eg, migraine, epilepsy, asthma). Cardiac or renal dysfunction. Pretreatment physical exam should include Pap smear and lab tests. May mask onset of climacteric. Monitor hepatic function periodically; temporarily interrupt if hepatic dysfunction develops. Discontinue if jaundice or liver dysfunction, visual disturbances, migraine, or thrombotic disorders occur. Pregnancy. Nursing mothers.
May be antagonized by aminoglutethimide. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John's wort). May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.
Menstrual irregularities (eg, bleeding, amenorrhea, spotting), nausea, edema/fluid retention, facial swelling, weight gain, dizziness, headache, nervousness, corticoid-like effects, hypersensitivity; decreased BMD, acne, inj site reactions (eg, pain/tenderness, persistent atrophy/indentation/dimpling, nodule/lump).